Researchers from the University of Southampton have demonstrated, in early studies, that adding an immune response stimulating drug called a ‘STING agonist’ could overcome drug-resistance to monoclonal antibodies, such as rituximab, a form of immunotherapy used to treat lymphoma.
This groundbreaking research, which could pave the way for improved patient outcomes, is being led by the University’s Dr Stephen Beers and Professor Mark Cragg.
Results from the study, which was funded by the charities Bloodwise and Cancer Research UK, are published in the journal Cancer Research.
